ARF6 and ovarian cancer: Combined analysis of CYTH2‐ARF6‐AGAP1 module mRNA levels in ovarian cancer patients indicated that high levels of all three components (blue line; upper grouping based on median split of each gene's expression, M2) showed a significant, 17‐month decrease in survival compared to low levels (red line, M1; P = 3.264e‐3; Fig 7I).